In one of the first studies of its kind, Columbia’s Philip De Jager shows how “big data” analyses may lead to new treatment strategies for Alzheimer’s disease.
Columbia neurologist William Kreisl, MD, explains the potential uses—and limitations—of a smell test in sniffing out Alzheimer's disease risk.
Clinical trial shows that solanezumab, an antibody-based treatment for Alzheimer’s disease, does not significantly slow cognitive decline.
Researchers at Columbia University found that dementia is on the decline in seniors from northern Manhattan, following national trends.
A new study suggests a smell test can identify people with mild cognitive impairment–often a precursor to Alzheimer’s–who may benefit from cholinesterase inhibitors.
Scientists propose a new model for Alzheimer's disease that may explain the high failure rate of recent clinical trials.